Eagle Pharmaceuticals identified material weaknesses in internal control

Eagle Pharmaceuticals disclosed that is has identified material weaknesses in its internal control over financial reporting that existed as of June 30, and has re-evaluated the effectiveness of the company’s disclosure controls and procedures as of June 30. Based on this assessment, the company’s disclosure controls and procedures were ineffective as of June 30. The company is continuing to evaluate its internal control over financial reporting and will report its remediation plan and further information regarding the material weaknesses. Eagle intends to file an amendment to its previously filed Form 10-Q for the quarter ended June 30, which will include restated unaudited condensed consolidated financial statements for the three and six months ended June 30.